PubRank

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

Clinical Trial ID NCT00593450

PubWeight™ 67.93‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00593450

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 19.42
2 Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012 11.91
3 Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013 3.85
4 Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013 2.82
5 Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2012 2.19
6 Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011 2.05
7 Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med 2010 1.84
8 Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2012 1.73
9 Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2012 1.70
10 Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013 1.57
11 Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014 1.45
12 Antibody fragments: hope and hype. MAbs 2010 1.42
13 Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012 1.40
14 Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014 1.20
15 Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013 1.07
16 Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2016 1.04
17 Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014 0.99
18 VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol 2014 0.92
19 Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2014 0.89
20 Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2016 0.88
21 Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2014 0.87
22 Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2015 0.86
23 Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015 0.85
24 Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013 0.84
25 Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015 0.84
26 Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol 2014 0.83
27 Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014 0.83
28 Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol 2014 0.82
29 Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2015 0.82
30 Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2015 0.82
31 VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology 2015 0.79
32 Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2016 0.78
33 The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age-related macular degeneration. Clin Ophthalmol 2011 0.77
34 Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol 2016 0.76
35 Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015 0.76
36 Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Adv Ther 2016 0.75
Next 100